🇺🇸 FDA
Pipeline program

GSK221149A

OTA105256

Phase 2 small_molecule completed

Quick answer

GSK221149A for Obstetric Labour, Premature is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline
Indication
Obstetric Labour, Premature
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials